FDA Approves Stiolto® Respimat® sNDA to Add Data on COPD | BI US
FDA approves labeling for Stiolto® Respimat® (tiotropium bromide & olodaterol) with data showing reduction in COPD exacerbations. View ISI, PI & Med Guide.
US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.